TW202317543A - 表皮生長因子受體抑制劑之鹽與晶型 - Google Patents

表皮生長因子受體抑制劑之鹽與晶型 Download PDF

Info

Publication number
TW202317543A
TW202317543A TW111123214A TW111123214A TW202317543A TW 202317543 A TW202317543 A TW 202317543A TW 111123214 A TW111123214 A TW 111123214A TW 111123214 A TW111123214 A TW 111123214A TW 202317543 A TW202317543 A TW 202317543A
Authority
TW
Taiwan
Prior art keywords
compound
salt
egfr
fumarate
crystalline
Prior art date
Application number
TW111123214A
Other languages
English (en)
Chinese (zh)
Inventor
艾瑞卡 巴勒
凱特琳 Ｎ 金凱瑪
克利斯多福 李
Original Assignee
美商纜圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商纜圖藥品公司 filed Critical 美商纜圖藥品公司
Publication of TW202317543A publication Critical patent/TW202317543A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW111123214A 2021-06-23 2022-06-22 表皮生長因子受體抑制劑之鹽與晶型 TW202317543A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163214089P 2021-06-23 2021-06-23
US63/214,089 2021-06-23

Publications (1)

Publication Number Publication Date
TW202317543A true TW202317543A (zh) 2023-05-01

Family

ID=82608408

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123214A TW202317543A (zh) 2021-06-23 2022-06-22 表皮生長因子受體抑制劑之鹽與晶型

Country Status (9)

Country Link
US (1) US20240293404A1 (https=)
EP (1) EP4359400B1 (https=)
JP (1) JP2024523506A (https=)
CN (1) CN117836287A (https=)
CA (1) CA3223859A1 (https=)
ES (1) ES3042447T3 (https=)
IL (1) IL309469A (https=)
TW (1) TW202317543A (https=)
WO (1) WO2022271846A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
AR126196A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Proceso para preparar inhibidores de egfr

Also Published As

Publication number Publication date
CA3223859A1 (en) 2022-12-29
WO2022271846A1 (en) 2022-12-29
JP2024523506A (ja) 2024-06-28
ES3042447T3 (en) 2025-11-20
EP4359400B1 (en) 2025-07-02
EP4359400A1 (en) 2024-05-01
IL309469A (en) 2024-02-01
US20240293404A1 (en) 2024-09-05
CN117836287A (zh) 2024-04-05

Similar Documents

Publication Publication Date Title
CN113993590B (zh) 新型egfr抑制剂
JP7296906B2 (ja) 組合せ
TW202317543A (zh) 表皮生長因子受體抑制劑之鹽與晶型
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
CA3079012A1 (en) Crystalline forms
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN118221698A (zh) Kras g12d抑制剂
US20190381048A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN107540661A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN108026095B (zh) 新化合物
WO2019084285A1 (en) FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
JP2017512792A (ja) Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
CN112142745B (zh) 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用
CN110903283B (zh) 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
TW201808948A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它們在治療癌症中之用途
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
CN104557870B (zh) 一种吡啶胺化合物的富马酸盐
CN103626761B (zh) 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
CN103509024B (zh) 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
HK40104230A (zh) 表皮生长因子受体抑制剂的盐和晶体形式
KR20180052631A (ko) 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
CN114805301B (zh) 2,4-二芳氨基嘧啶类化合物及其制备方法和应用
CN106632254B (zh) 一种取代的喹啉化合物的晶型及其药物组合物和用途
EP4229038A1 (en) Dosing regimens for cyclin-dependent kinase 7 (cdk7) inhibitors
WO2023011299A1 (zh) 嘧啶-4,6-二胺衍生物及其制备方法和药学上的应用